NeoGenomics (NEO)

• Market cap: $1.43B
• 1 day: -6.41%
• 5 days: -20.43%
• 1 month: -21.72%
• 3 months: -27.88%
• 6 months: -32.44%
• Year to date: -32.69%
• 1 year: -32.65%
• 5 years: -65.84%
• 10 years: 153.42%
• Sector: Industrials
• Industry: Testing Laboratories

About: NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

Employees: 2,200

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

789% more call options, than puts

Call options by funds: $15.6M | Put options by funds: $1.76M

11% more capital invested

Capital invested by funds: $1.82B [Q3] → $2.02B (+$195M) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]

1.19% less ownership

Funds ownership: 96.69% [Q3] → 95.5% (-1.19%) [Q4]

7% less funds holding

Funds holding: 267 [Q3] → 247 (-20) [Q4]

21% less repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 96

34% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 32

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $16 44% upside
• Avg. target: $18.50 67% upside
• High target: $22 98% upside

4 analyst ratings

• positive: 3 75%
• neutral: 1 25%
• negative: 0 0%

B of A Securities Derik De Bruin 45% 1-year accuracy 9 / 20 met price target	44% upside $16	Neutral Maintained	19 Feb 2025
Needham Mike Matson 55% 1-year accuracy 67 / 122 met price target	62% upside $18	Buy Maintained	19 Feb 2025
Goldman Sachs Matthew Sykes 56% 1-year accuracy 22 / 39 met price target	62% upside $18	Buy Maintained	28 Jan 2025
Jefferies Tycho Peterson 47% 1-year accuracy 7 / 15 met price target	98% upside $22	Buy Initiated	10 Dec 2024